HEALTH OF WOMAN. 2019.7(143): 90–94; doi 10.15574/HW.2019.143.90
O.O. Samokhvalova
The National Cancer Institute Ministry of health of Ukraine, Kyiv

The article presents the results of diagnostic value the qualitative test of cyclooxygenase-2 (COX-2) in tumors of the external genital organs in women.

The objective: to evaluate the expression of the molecular marker COX-2 depending on the clinical, topographic, histological and morphological features of tumors of the external genital organs.

Materials and methods. A prospective follow-up of 131 women with external genital tumors was conducted. In all clinical cases, a qualitative COX-2 test was performed.

Results. When determining the diagnostic value of a qualitative COX-2 test for FIGO clinical staging, the «chances» (OR) of detecting COX-2 positive in patients increased at stages III (OR – 2.41) and IV (OR – 3.88). During TNM-staging, the reliable value of the qualitative analysis of COX-2 was verified at the T3 stage (78.6%), T4 stage (100.0%), as well as in the presence of Tx (100.0%).

In the presence of metastases in the lymph nodes, the number of COX-2-positive clinical cases, depending on the degree of damage to the lymph nodes, increased to 44.4% with N1 (an increase of 1.92 times) compared with 29.3% with N0, reaching 50, 0% at N2 (the probability of metastasis increased by 2.41 times).

It was proved that in the absence of distant metastases (M0), the proportion of COX-2-positive cases was 33.1%, and in the presence of (M1) it was 50.0%. The «chances» of distant metastases increased from 1.97 at M0 to 4.0 at M1.

Reliable diagnostic value of a qualitative COX-2 test from the degree of differentiation of primary tumors of the external genital organs was established: in the presence of a high degree of differentiation, the detection rate reached 24.5% (OR – 1.0), with a moderate degree – 35.4% (OR – 1.68), in the presence of a low degree of differentiation – 44.0% (OR – 2.60), with undifferentiated tumors – 100.0% (OR – 10.0).

When assessing the morphological features of the tumor, the diagnostic informativeness of the qualitative test was confirmed in the presence of undifferentiated cancer in 100.0% of cases (OR – 5.0), adenocarcinomas – in 60.0% of cases (OR – 2.83), malignant melanoma – 40, 0% of cases (OR – 1.25), as well as squamous keratinizing – 32.0% (OR – 1.0) and squamous non-keratinizing cancer – 36.0% (OR – 1.07).

Conclusion. For the assessment of localization of the primary tumor, the greatest diagnostic value of the qualitative test was established for total lesion (100.0%, OR-2.0), labia majora pudendi (40.0%, OR-1.29) and vulva (34, 1%, OR – 1.0).

Key words: cyclooxygenase-2, qualitative test, diagnostic value, tumors of external genital organs, women.

REFERENCES

1. Rebrova OYu. 2004. Statisticheskiy analiz meditsinskih dannyih. Primenenie paketa prikladnyih programm STATISTICA. M, Media-sfera:312.

2. Fons G, Burger MP, ten Kate FJ, van der Velden J. 2009. Assessment of promising protein markers for vulva cancer. Int J Gynecol Cancer. 19(4):756-60. https://doi.org/10.1111/IGC.0b013e3181a4071d; PMid:19509584

3. Haddad H, Engohan-Aloghe C, Belhaj S et al. 2015. A very misleading vulvar tumor. Ann. Pathol. 35(4): 368-370. https://doi.org/10.1016/j.annpat.2015.01.003; PMid:25795387

4. Haffty BG, Yang Q, Moran MS. 2008. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys. 71 (4): 1006–1013. https://doi.org/10.1016/j.ijrobp.2007.11.063; PMid:18262731

5. Hennequart M, Pilotte L, Cane S, Hoffmann D et al. 2017. Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance. Cancer Immunol Res. 5(8): 695-709. https://doi.org/10.1158/2326-6066.CIR-16-0400; PMid:28765120

6. Horn LC, Purz S, Krumpe C. 2008. COX-2 and Her-2-neu are overexpressed in Paget’s disease of the vulva and the breast: results of a preliminary study. Arch Gynecol Obstet. 277 (2): 135–138. https://doi.org/10.1007/s00404-007-0434-1; PMid:17701193

7. Hu M, Peluffo G, Chen H. 2009. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A. 106 (9): 3372–3377. https://doi.org/10.1073/pnas.0813306106; PMid:19218449 PMCid:PMC2642666

8. Jawanjal P, Salhan S, Dhawan I, Das N et al. 2016. Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients With Cervical Cancer. J Clin Lab Anal. 30(6): 1198-1207. https://doi.org/10.1002/jcla.22003; PMid:27292107 PMCid:PMC6807097

9. Ko SH, Choi GJ, Lee JH et al. 2008. Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma. Oncol Rep. 19 (2): 425–433. https://doi.org/10.3892/or.19.2.425; PMid:18202791

10. Mitchell A, Newton JM, Brite K, Einspahr J et al. 2007. Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer. J Low Genit Tract Dis. 11(2):80-5. https://doi.org/10.1097/01.lgt.0000236969.27502.71

11. Raspollini MR, Asirelli G, Taddei GL. 2007. The role of angiogenesis and COX-2 expression in the evolution of vulvar lichen sclerosus to squamous cell carcinoma of the vulva. Gynecol Oncol. 106(3): 567-71. https://doi.org/10.1016/j.ygyno.2007.05.007; PMid:17560634

12. Sunita BS, Sen A, Suhag V. 2018. To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor. J Cancer Res Ther. 14(6): 1366-1372.

13. Torricelli F, Mandato VD, Farnetti E, Abrate M et al. 2015. Polymorphisms in cyclooxygenase-2 gene in endometrial cancer patients. Tumour Biol. 36(10): 7423-30. https://doi.org/10.1007/s13277-015-3424-0; PMid:25900875

14. Wang X, Colby JK, Yang P. 2008. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue. Carcinogenesis. 29 (1): 120–128. https://doi.org/10.1093/carcin/bgm226; PMid:17942462

15. Zhang XH, Huang DP, Guo GL. 2008. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer. 8:4. https://doi.org/10.1186/1471-2407-8-4; PMid:18190720 PMCid:PMC2253544